UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCSF Helen Diller Family Comprehensive Cancer Center


Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma

June 07, 2022

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

Sacituzumab Govitecan Demonstrates Significant Clinical Benefit in HR+/HER2- Metastatic Breast Cancer

June 04, 2022

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.

Frontline Therapy Advances Are Current Focus in SCLC and NSCLC

April 18, 2022

Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.

Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma

March 23, 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC

November 26, 2021

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

Investigators Aim to Identify New Treatment Targets with Cancer Cell Map Initiative

November 16, 2021

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.